Barinthus Biotherapeutics has a powerful suite of innovative technologies to create more effective immunotherapies for the treatment of infectious diseases, cancer and autoimmunity.

Our proprietary platforms, ChAdOx, MVA, SNAP-TI and SNAP-CI, are enabling the company to develop antigen-specific immunotherapeutics that aim to optimize the disease-fighting capabilities of T cells and guide them towards a healthy balance. This is achieved through increasing disease specific CD8 T cell activity in the case of infectious diseases and cancers, or dampening CD4 and CD8 T cells, and increasing T Regulatory cells in autoimmunity.


Viral Vector Platforms

ChAdOx1 (Chimpanzee Adenovirus Oxford) and ChAdOx2 are modified, replication-incompetent simian adenoviral vectors. Modified Vaccinia Ankara (MVA) is a well-studied, attenuated Vaccinia virus. Both vectors encode the target antigen.
Immunisation with ChAdOx potently primes T cells against the target antigen. A second immunisation with MVA boosts and expands the T cell response against the target antigen.

This approach reproducibly achieves immune responses that are differentiated by their high magnitude, high quality, and highly durable antigen-specific CD4+ helper and CD8+ cytotoxic T cells. These characteristics are ideal for immunotherapies designed to treat infectious disease and cancer.

Synthetic Platforms

This fully synthetic and biocompatible platform utilizes self-assembly to co-deliver multiple antigens and immunomodulators in nanoparticles of precise, programmable size and composition for inducing the specific T cell populations needed for diverse therapeutic indications ranging from cancer to autoimmunity.